全文获取类型
收费全文 | 5531篇 |
免费 | 403篇 |
国内免费 | 68篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 252篇 |
妇产科学 | 106篇 |
基础医学 | 735篇 |
口腔科学 | 104篇 |
临床医学 | 458篇 |
内科学 | 1472篇 |
皮肤病学 | 329篇 |
神经病学 | 552篇 |
特种医学 | 404篇 |
外科学 | 376篇 |
综合类 | 25篇 |
预防医学 | 277篇 |
眼科学 | 47篇 |
药学 | 335篇 |
1篇 | |
中国医学 | 7篇 |
肿瘤学 | 496篇 |
出版年
2024年 | 9篇 |
2023年 | 54篇 |
2022年 | 98篇 |
2021年 | 191篇 |
2020年 | 129篇 |
2019年 | 144篇 |
2018年 | 158篇 |
2017年 | 133篇 |
2016年 | 162篇 |
2015年 | 201篇 |
2014年 | 241篇 |
2013年 | 290篇 |
2012年 | 347篇 |
2011年 | 343篇 |
2010年 | 198篇 |
2009年 | 264篇 |
2008年 | 274篇 |
2007年 | 294篇 |
2006年 | 269篇 |
2005年 | 250篇 |
2004年 | 218篇 |
2003年 | 221篇 |
2002年 | 176篇 |
2001年 | 51篇 |
2000年 | 44篇 |
1999年 | 57篇 |
1998年 | 139篇 |
1997年 | 134篇 |
1996年 | 127篇 |
1995年 | 98篇 |
1994年 | 103篇 |
1993年 | 109篇 |
1992年 | 26篇 |
1991年 | 26篇 |
1990年 | 27篇 |
1989年 | 50篇 |
1988年 | 44篇 |
1987年 | 34篇 |
1986年 | 37篇 |
1985年 | 43篇 |
1984年 | 22篇 |
1983年 | 19篇 |
1982年 | 22篇 |
1981年 | 36篇 |
1980年 | 24篇 |
1979年 | 9篇 |
1978年 | 8篇 |
1977年 | 22篇 |
1976年 | 19篇 |
1975年 | 6篇 |
排序方式: 共有6002条查询结果,搜索用时 15 毫秒
1.
Eglantina Idrizaj Rachele Garella Roberta Squecco Maria Caterina Baccari 《World journal of gastroenterology : WJG》2020,26(20):2472-2478
The regulation of food intake is a complex mechanism, and the hypothalamus is the main central structure implicated. In particular, the arcuate nucleus appears to be the most critical area in the integration of multiple peripheral signals.Among these signals, those originating from the white adipose tissue and the gastrointestinal tract are known to be involved in the regulation of food intake.The present paper focuses on adiponectin, an adipokine secreted by white adipose tissue, which is reported to have a role in the control of feeding by acting centrally. The recent observation that adiponectin is also able to influence gastric motility raises the question of whether this action represents an additional peripheral mechanism that concurs with the central effects of the hormone on food intake. This possibility, which represents an emerging aspect correlating the central and peripheral effects of adiponectin in the hunger-satiety cycle, is discussed in the present paper. 相似文献
2.
Alessia Scarselli Silvia Di Cesare Claudia Capponi Simona Cascioli Maria L. Romiti Gigliola Di Matteo Alessandra Simonetti Paolo Palma Andrea Finocchi Barbarella Lucarelli Rita M. Pinto Ippolita Rana Giuseppe Palumbo Maurizio Caniglia Paolo Rossi Rita Carsetti Caterina Cancrini Alessandro Aiuti 《Journal of clinical immunology》2015,35(4):373-383
3.
4.
5.
Rocco Spagnuolo Alessandro Corea Mariantonietta Blumetti Alessia Giovinazzo Massimiliano Serafino Caterina Pagliuso Raffaele Pagnotta Grazia Curto Cristina Cosco Vincenzo Cosco Rosellina Margherita Mancina Pietro Garieri Anna Papaleo Laura Grande Anna Barilaro Eugenio Garofalo Andrea Bruni Patrizia Doldo 《Journal of advanced nursing》2020,76(11):2993-3002
6.
7.
Caterina Proto Daniela Romualdi Rosa Maria Cento Rosario S Spada Giuseppina Di Mento Raffaele Ferri Antonio Lanzone 《Gynecological endocrinology》2006,22(4):213-218
BACKGROUND: In the central nervous system, several neuropeptides are believed to be involved in the pathophysiology of Alzheimer's disease (AD). Indeed, previous studies have documented that glucagon-like peptide 1 (GLP-1) possesses neurotropic properties and can reduce amyloid-beta peptide levels in the brain in vivo. Moreover, the concentrations of neuropeptide Y (NPY) seem to be altered in the cerebrospinal fluid of patients with AD and in subjects with major depression. Finally, among the modifications induced by aging, a dysregulation of the ghrelin-growth hormone (GH) system has been reported. METHODS: We investigated the plasma concentrations of these neuropeptides in 14 subjects with AD. Data obtained from these patients were compared with data from an age- and weight-matched healthy group. RESULTS: No significant differences were found between the two groups in relation to plasma levels of GLP-1, NPY, ghrelin and GH. Peripheral NPY concentrations were positively correlated with ghrelin levels in both groups, and with plasma GLP-1 concentration only in controls. CONCLUSION: On the basis of our results, peripheral levels of these neuropeptides seem not to serve as biochemical markers of AD. 相似文献
8.
Birth weight on 12,644 singleton infants from 6,196 sibships born in Maryland between 1980 and 1984 were used to estimate the effects of nine maternal and infant covariates on the sibship correlation in birth weight. Assuming a homogeneous correlation across all families, the estimated intraclass correlation was 0.4664 (+/- 0.0099). This high sibship correlation makes it possible to predict, with reasonable accuracy, the birth weight of a child given information on previous sibs, as well as covariates on the mother and/or infant pertinent to a given pregnancy. The reduction in variance associated with incorporating information on the nine covariates used here was approximately equal to that obtained by conditioning on a single previous sib. Testing for heterogeneity in correlation among different groups of families showed that a crude measure of parity (first live birth vs. other), time between births, mother's marital status, and maternal age at the birth of the last child significantly influenced the sibship correlation in birth weight. 相似文献
9.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
10.
CM Reid M. Nelson P. Beckinsale P. Ryan LMH Wing LJ Beilin MA Brown GLR Jennings CI Johnston J. Marley JJ McNeil TO Morgan J. Shaw ID Steven MJ West 《Clinical and experimental pharmacology & physiology》1997,24(5):370-373
1. The present study aimed to determine the feasibility of conducting a 5 year cardiovascular outcome trial of the treatment of 6000 elderly hypertensive patients in Australian general practices. 2. General practitioners (GPs) were invited to participate by mail and personal follow-up. Patient records were reviewed to identify subjects for a blood pressure (BP) screening programme. Blood pressure was measured on three occasions and eligible subjects were included if the average BP was 160 mmHg systolic or 90 mmHg diastolic if systolic BP was 140 mmHg. 3. Seven hundred and forty-one GPs were approached and 89 were enrolled in the study (12% of mail invites and 75% of those receiving a personal contact). In 16 practices where screening was completed, 82 000 records were reviewed to identify 4% patients eligible for screening. Twenty-two per cent of eligible subjects attended screening. Of 1938 subjects screened, 180 (9%) had BP 5=160/90 mmHg. Forty-seven percent of subjects (n = 916) were receiving antihypertensive therapy and 184 (20%) were withdrawn from therapy. One hundred and sixteen (63%) of these subjects had BP return to study entry levels within 6 weeks. Fifty-seven newly diagnosed and 81 previously treated subjects were randomized (7% of the screened population). 4. Based on the high participation rate of GPs, the response rate of patients to attend a BP screening programme and the 7% randomization to screening ratio for entry into the study, the ANBP2 pilot study has demonstrated that it is feasible to recruit subjects from Australian general practices to a cardiovascular outcome trial. 相似文献